Business Wire

KIRIN-HOLDINGS

5.8.2022 04:02:10 CEST | Business Wire | Press release

Share
Kirin Holdings’ Long-term GHG Reduction Target Was Approved by the Science Based Targets*1 Initiative Based on Science-based Net-zero Targets

Kirin Holdings Company, Limited (Kirin Holdings) has been approved as the first world company in the food and beverage processing sector with science-based net-zero targets validated by SBTi * 2 in July 2022. The Kirin Group’s long-term GHG reduction target , "realizing net-zero* 3 GHG* 4 emission from the entire value chain by 2050" set forth in the Kirin Group Environmental Vision 2050 was certified as a scientifically based goal consistent with the level of GHG emission reductions required by the Paris Agreement* 5 .

Kirin Holdings, with the aim of becoming " A global leader in CSV* 6 ”, have declared our goal of achieving net-zero emissions by 2020 under the Kirin Group Environmental Vision 2050 and have formulated a roadmap for achieving the goal, which went into operation in January 2022.

A sense of crisis was shared around the world on the issue of climate change in the wake of the 2015 Paris Agreement, the 2018 IPCC 1.5°C Special Report* 7 reported that global warming from pre-industrial times must be limited to 1.5°C and GHG emissions must be reduced to net zero by around 2050. In order to achieve that common global long-term goal, many companies in the world have set "2050 Net Zero" targets. However, since there is no common standard for corporate net-zero targets, the scope of GHG emissions to be covered, the means to achieve net-zero, and the level of GHG reductions differ, and thus a divergence from the target needed to limit global warming to 1.5°C has been pointed out.

In response to this flurry of net-zero targets, the SBT Initiative developed the "Net Zero Standard" in October 2021. This standard stipulates that in order to limit global warming to 1.5°C, companies must reduce GHG emissions by at least 90% across their value chains by 2050, and the net-zero can be achieved by removing the remaining 10% of GHG emissions from the atmosphere.

In order to achieve The Kirin Group’s long-term goal, Kirin Holdings has set a mid-term target for 2030 (to reduce the total of Scope 1 and Scope 2 for the entire group by 50% and Scope 3 by 30% by 2030 compared to 2019), and is promoting GHG reduction in our value chain with the technological capabilities we have cultivated over the years. For Scope 1 and Scope 2, we have installed heat pumps at six Kirin Brewery breweries in Japan, utilizing our plant engineering capabilities to reduce GHG emissions by approximately 3,800 tons per year. In terms of Scope 3, we are gradually expanding the use of "R100 PET bottles" made of 100% recycled PET resin, and are rolling them out for some of our Kirin Nama-cha brands.

With the goal of achieving net zero emissions by 2050, Kirin Holdings will continue to work toward the realization of the Kirin Group Environmental Vision 2050, which aims to strengthen the resilience of society and the company, and to lead the way toward the creation of a decarbonized society.

1:

Science Based Targets: Greenhouse gas reduction targets based on scientific evidence.

2:

An international initiative jointly established in 2015 by CDP, the UN Global Compact, the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF).

3:

A state in which anthropogenic GHG emissions and removals are balanced and GHG emissions to the atmosphere are net zero.

4:

Green House Gas

5:

International framework for global warming countermeasures in which all countries and regions participate

6:

Creating Shared Value. Combined added value for consumers as well as for society at large.

7:

This report published by the Intergovernmental Panel on Climate Change (IPCC) describes the significant difference between 2°C and 1.5°C in terms of the impact of future temperature increases and the emission pathways to limit the increase to 1.5°C.

[Reference]
・Kirin Group Environmental Vision 2050
https://www.kirinholdings.com/en/impact/env/mission/

About Kirin Holdings

Kirin Holdings Company, Limited is an international company that operates in the Food & Beverages domain (Food & Beverages businesses), Pharmaceuticals domain (Pharmaceuticals businesses), and Health Science domain (Health Science business), both in Japan and across the globe.

Kirin Holdings can trace its roots to Japan Brewery which was established in 1885. Japan Brewery became Kirin Brewery in 1907. Since then, the company expanded its business with fermentation and biotechnology as its core technologies, and entered the pharmaceutical business in the 1980s, all of which continue to be global growth centers. In 2007, Kirin Holdings was established as a pure holding company and is currently focusing on boosting its Health Science domain.

Under the Kirin Group Vision 2027 (KV 2027), a long-term management plan launched in 2019, the Kirin Group aims to become “A global leader in CSV, creating value across our world of Food & Beverages to Pharmaceuticals.” Going forward, the Kirin Group will continue to leverage its strengths to create both social and economic value through its businesses, with the aim of achieving sustainable growth in corporate value.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release

IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million

IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release

IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p

HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release

HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha

Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release

Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char

DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release

Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye